Promoter holding
64.27%
GP
Glenmark Pharmaceuticals Limited - Due diligence report
A 360° intelligence report on Glenmarkpharma: trust score, financial health, credit view, compliance, directors, growth and distress signals…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Glenmarkpharma — 360° Intelligence Report
Generated from MCA filings & public records81/100
Trust Score
Low Risk
Glenmarkpharma is assessed as Low Risk with a Trust Score of 81/100. Glenmarkpharma is an active public limited indian non-government company incorporated in 1977, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 01 Aug 2026 from the latest processed filings. Glenmark Pharmaceuticals Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
81/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
72/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
85/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
45/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 85/100 Low Risk
- Moderate gearing (D/E 38%).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (A1).
Charges position: 1 open (890.00 cr) · 13 satisfied (1,040.00 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Bank Of India | 3 | 48.0 cr |
| The Hongkong And Shanghai Banking Corporation Limited | 2 | 48.0 cr |
| Central Bank Of India | 1 | 48.0 cr |
| Axis Bank Limited | 1 | 48.0 cr |
| State Bank Of India | 2 | 48.0 cr |
| State Bank Of Indai | 1 | 48.0 cr |
Compliance Score: 72/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 4 court forum(s).
- Delayed payments to MSME suppliers disclosed (99 disclosure(s)).
- 12 active GST registration(s).
Legal cases on record (4)
05
Director Intelligence
Stability score: 45/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| GLENN MARIO SALDANHA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DIPANKAR BHATTACHARJEE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| BLANCHE SALDANHA ELIZABETH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| V S MANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SONA SAIRA RAMASASTRY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANURAG MANTRI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PRADEEP KUMAR SINHA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RASHMI KHANDELWAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HARISH VINAYAK KUBER | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| CHERYLANN MARIA PINTO | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIJAYALAKSHMI RAJARAM IYER | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Patricia Susan Andrews | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 12 directors on the board.
- RASHMI KHANDELWAL has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2025)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
1
Group entities
1
Capital events
5 allotment(s) · 0 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Glenmark Pharmaceuticals (australia) Pty Ltd | Subsidiary Company | 74.00% |
| Glenmark Pharmaceuticals (nigeria) Ltd | Subsidiary Company | 74.00% |
| Glenmark Pharmaceuticals B.v. | Subsidiary Company | 74.00% |
| Glenmark Pharmaceuticals Canada Inc. | Subsidiary Company | 74.00% |
| Glenmark Pharmaceuticals Colombia Sas, Colombia | Subsidiary Company | 74.00% |
| Glenmark Pharmaceuticals Distribution S.r.o. | Subsidiary Company | 74.00% |
| Glenmark Pharmaceuticals Ecuador S.a. | Subsidiary Company | 74.00% |
| Glenmark Pharmaceuticals Egypt S.a.e. | Subsidiary Company | 74.00% |
| Glenmark Pharmaceuticals Europe Ltd., U.k. | Subsidiary Company | 74.00% |
| Glenmark Pharmaceuticals Fze | Subsidiary Company | 74.00% |
Key managerial personnel: GLENN MARIO SALDANHA (Managing Director) · V S MANI (CFO) · ANURAG MANTRI (Whole-time director) · CHERYLANN MARIA PINTO (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 80 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
EPFO headcount growing - hiring signal.
Operating for 48+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
1 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 4.04 cr.
4 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence80/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment85/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 890.00 cr already registered.
- Compliance record supports lending.
Investor view86/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events22 Jul 2026
Director appointed
RASHMI KHANDELWAL (Nodal Officer)
26 Sep 2025
Last AGM held
Annual general meeting
14 Aug 2025
Director appointed
Patricia Susan Andrews (Director)
27 May 2025
Director appointed
ANURAG MANTRI (Whole-time director)
31 Mar 2025
Latest balance sheet
Filed with ROC
14 Feb 2025
Director appointed
PRADEEP KUMAR SINHA (Director)
31 Mar 2024
Director ceased
SRIDHAR GORTHI
10 Feb 2023
Director appointed
VIJAYALAKSHMI RAJARAM IYER (Director)
22 Jun 2022
Charge satisfied
State Bank Of India
05 May 2022
Charge satisfied
Bank Of India
14 Aug 2020
Director appointed
DIPANKAR BHATTACHARJEE (Director)
26 Jun 2020
Director ceased
JULIO FRANCIS RIBEIRO
01 Apr 2019
Director appointed
SONA SAIRA RAMASASTRY (Director)
28 Sep 2018
Director ceased
V S MANI
29 May 2018
Director ceased
MURALI NEELAKANTAN
10
Key Observations
Auto-generated from the data aboveRevenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - manageable leverage.
Net worth is positive.
12 active director(s) / partner(s); review board churn before relying on management continuity.
12 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of A1 from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 5 security allotment(s) - amounts available in the full report.
340 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Pg | U24240MH1989PTC050398 | Mumbai, Maharashtra, India |
| Macleods | U24239MH1989PLC052049 | Mumbai, Maharashtra, India |
| Dabur | L24230DL1975PLC007908 | New Delhi, Delhi, India |
| Divi'S | L24110TG1990PLC011854 | Hyderabad, Telangana, India |
| Torrent Pharmaceuticals | L24230GJ1972PLC002126 | Daskroi, Gujarat, India |
| Gujarat State Fertilizers & Chemicals | L99999GJ1962PLC001121 | Vadodara, Gujarat, India |
| Mankind Pharma | L74899DL1991PLC044843 | New Delhi, Delhi, India |
| Dow | U24239MH1998PTC113551 | Thane, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Glenmarkpharma before audits and certifications: compliance score 72/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Glenmarkpharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 85/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Glenmarkpharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 81/100, distress signals and MSME payment-delay disclosures - know whether Glenmarkpharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Glenmarkpharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Glenmarkpharma an active company?
Glenmarkpharma has MCA status “Active” with a compliance score of 72/100 (Moderate).
Is Glenmarkpharma financially healthy?
Glenmarkpharma has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Glenmarkpharma?
Its overall Trust Score is 81/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Glenmarkpharma?
Promoters hold a minority stake - exact percentages are in the full report. 12 active director(s) are on record.
Does Glenmarkpharma have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 13 earlier charge(s) stand satisfied.
Is Glenmarkpharma up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 72/100 (Moderate).
Is it risky to lend to Glenmarkpharma?
Its Credit Risk Score is 85/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
